Analyst firms · Raymond James · PTCT

Raymond James PTCT price target and rating history

PTC Therapeutics Inc. (PTCT) · Health Care

Raymond James rates PTC Therapeutics Inc. (PTCT) Outperform with a $108 price target, as of its latest action on Apr 10, 2026. It has published 5 rating actions on PTCT since October 2021, including 1 upgrade and 1 downgrade. Across 8 firms with a PTCT price target in the last 12 months, the median target is $94.50. Raymond James's $108 is 14% above that.

Current rating
Outperform
Price target
$108
Median target, all firms
$94.50
Actions on PTCT
5

Raymond James price target on PTCT

$108$82$5520222023202420252026
Raymond James price target on PTCT, each point a stated target, October 2021 to April 2026.

Every Raymond James rating on PTCT

How other firms rate PTCT

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Truist SecuritiesHold$62Oct 16, 2026
Leerink PartnersOutperform$98Sep 14, 2026
CitigroupBuy$108Jun 9, 2026
JefferiesBuy$85May 27, 2026
TD CowenBuy$90May 8, 2026
Raymond JamesOutperform$108Apr 10, 2026
BarclaysOverweight$119Jan 28, 2026
RBC Capital MarketsSector Perform$91Dec 1, 2025

Questions about Raymond James and PTCT

What is Raymond James's price target for PTCT?
Raymond James's latest stated price target for PTC Therapeutics Inc. (PTCT) is $108, from its action on Apr 10, 2026.
What is Raymond James's rating on PTCT?
Raymond James rates PTCT Outperform, a bullish rating, as of Apr 10, 2026.
When did Raymond James last change its view on PTCT?
On Apr 10, 2026, Raymond James starts coverage at Outperform, price target $108.
How does Raymond James's PTCT target compare with other analysts?
Across 8 firms with a PTCT price target in the last 12 months, the median target is $94.50. Raymond James's $108 is 14% above that.

More PTCT rating histories

All Raymond James ratingsPTCT news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.